Uncategorized

CellCentric raises $220M to get multiple myeloma pill to market

Published

on

CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options.

The 22-year-old transatlantic biotech has collected a $220 million Series D to finish its …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version